Vous êtes sur la page 1sur 32

WHO Drug Information, Vol. 16, No.

1, 2002

Recommended INN: List 47

International Nonproprietary Names for Pharmaceutical Substances (INN)


RECOMMENDED International Nonproprietary Names (Rec. INN): List 47
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (185) and Recommended (145) International Nonproprietary Names can be found in Cumulative List No. 10, 2002 (available in CD-ROM only).

Dnominations communes internationales des Substances pharmaceutiques (DCI)


Dnominations communes internationales RECOMMANDES (DCI Rec): Liste 47
Il est notifi que, conformment aux dispositions du paragraphe 7 de la Procdure suivre en vue du choix de Dnominations communes internationales recommandes pour les Substances pharmaceutiques [Actes off. Org. mond. Sant, 1955, 60, 3 (rsolution EB15.R7); 1969, 173, 10 (rsolution EB43.R9)] les dnominations ci-dessous sont choisises par lOrganisation mondiale de la Sant en tant que dnominations communes internationales recommandes. Linclusion dune dnomination dans les listes de DCI recommandes nimplique aucune recommandation en vue de lutilisation de la substance correspondante en mdecine ou en pharmacie. On trouvera dautres listes de Dnominations communes internationales proposes (185) et recommandes (145) dans la Liste rcapitulative No. 10, 2002 (disponible sur CD-ROM seulement ).

Denominaciones Comunes Internacionales para las Sustancias Farmacuticas (DCI)


Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 47
De conformidad con lo que dispone el prrafo 7 del Procedimiento de Seleccin de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolucin EB15.R7); 1969, 173, 10 (Resolucin EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuacin se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusin de una denominacin en las listas de las Denominaciones Comunes Recomendadas no supone recomendacin alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (185) y Recomendadas (145) se encuentran reunidas en Cumulative List No. 10, 2002 (disponible slo en CD-ROM).
81

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

Latin, English, French, Spanish: Recommended INN Chemical name or description; Molecular formula; Graphic formula DCI Recommande DCI Recomendada Nom chimique ou description; Formule brute; Formule dveloppe Nombre qumico o descripcin; Frmula emprica; Frmula desarrollada

acidum gadocoleticum gadocoletic acid

trihydrogen [3-[[(4S)-4-[bis[2-[bis[(carboxy-O)methyl]amino-N]ethyl]aminoN]-4-(carboxy-O)butanoyl]amino]-12-hydroxy-5-cholan-24-oato(6-)]= gadolinate(3-) trihydrogno[3-[[(4S)-4-[bis[2-[bis[(carboxy- O)mthyl]amino- N]thyl]aminoN]-4-(carboxy-O)butanoyl]amino]-12-hydroxy-5-cholan-24-oato(6-)]= gadolinate(3-) trihidrgeno[3-[[(4S)-4-[bis[2-[bis[(carboxi-O)metil]amino-N]etil]amino-N]4-(carboxi-O)butanoil]amino]-12-hidroxi-5-colan-24-ato(6-)]gadolinato(3-) C41H63GdN4O14


H3 C H CH3 H CH3 2H+ O 2C H N
3+

acide gadocoltique

cido gadocoltico

HO

H H

CO2H

O N H H N CO2 CO2

H H

O2C O2C

Gd

afeletecanum afeletecan afltcan

camptothecin, ester with N-[[p-[(3-O-methyl--L-fucopyranosyl)oxy]phenyl]= thiocarbamoyl]-L-histidyl-L-valine (2S)-2-[[(2S)-3-(1 H-imidazol-4-yl)-2-[[[[4-[(3- O-mthyl-6-dsoxy-L-galactopyranosyl)oxy]phnyl]amino]thiocarbonyl]amino]propanoyl]amino]3-mthylbutanoate de (4S)-4-thyl-3,14-dioxo-3,4,12,14-ttrahydro1H-pyrano[3,4:6,7]indolizino[1,2-b]quinolin-4-yle ster de la camptotecina con N-[[p-[(3-O-metil--L-fucopiranosil)oxi]fenil]= tiocarbamoil]-L-histidil-L-valina

afeletecn

82

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C45H49N7O11S
O N O O N H N S N H N O O N H H3C NH O CH3 H CH3

O CH3 HO HO OCH3 O

alfimeprasum alfimeprase alfimprase alfimeprasa

[3-L-serine]fibrolase-(3-203)-peptide (fibrolase : fibrinolytic enzyme isolated from Agkistrodon contrix contrix venom) [3-L-srine]fibrolase-(3-203)-peptide (fibrolase : enzyme fibrinolytique extraite de venin dAgkistrodon contrix contrix) [3-L-serina]fibrolasa-(3-203)-pptido (fibrolasa : enzime fibrinoltica extraida de veneno de Agkistrodon contrix contrix) C985H1541N285O301S12

SFPQRYVQ INEIYRPLNI NWRETDLLRR KHSTGVIQDH GANSCVMAAM NKP

LVIVADHRMN QFTLVGLEIW QRHDNAQLLT SAINLLVALT LSDQPSKLFS

TKYNGDSDKI SNQDLITVTS AIDFDGDTVG MAHELGHNLG DCSKKDYQTF

RQWVHQIVNT VSHDTLASFG LAYVGGMCQL MNHDGNQCHC LTVNNPQCIL

83

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

alicaforsenum alicaforsen

2'-deoxy-( R )-P-thioguanylyl-(3' 5')-2'-deoxy-( R )- P -thiocytidylyl(3' 5')-2'-deoxy-( R )- P -thiocytidylyl-(3' 5')-2'-deoxy-( R )- P-thiocytidylyl(3' 5')-2'-deoxy-( R )-P-thioadenylyl-(3' 5')-2'-deoxy-( R )- P-thioadenylyl(3' 5')-2'-deoxy-( R )- P -thioguanylyl-(3' 5')-2'-deoxy-( R )- P-thiocytidylyl(3' 5')-( R )- P-thiothymidylyl-(3' 5')-2'-deoxy-( R )-P-thioguanylyl(3' 5')-2'-deoxy-( R )- P -thioguanylyl-(3' 5')-2'-deoxy-( R )- P-thiocytidylyl(3' 5')-2'-deoxy-(R )- P-thioadenylyl-(3' 5')-(R )- P-thiothymidylyl(3' 5')-2'-deoxy-( R )- P -thiocytidylyl-(3' 5')-2'-deoxy-( R )- P-thiocytidylyl(3' 5')-2'-deoxy-(R )- P-thioguanylyl-(3' 5')-(R )- P-thiothymidylyl(3' 5')-2'-deoxy-( R )- P-thiocytidylyl-(3' 5')-2'-deoxyadenosine nonadecasodium salt 2'-dsoxy-( R )- P -thioguanylyl-(3' 5')-2'-dsoxy-( R )- P -thiocytidylyl(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl-(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl(3' 5')-2'-dsoxy-( R )- P-thioadnylyl-(3' 5')-2'-dsoxy-(R )- P -thioadnylyl(3' 5')-2'-dsoxy-( R )- P-thioguanylyl-(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl(3' 5')-( R )- P-thiothymidylyl-(3' 5')-2'-dsoxy-( R )- P-thioguanylyl(3' 5')-2'-dsoxy-( R )- P-thioguanylyl-(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl(3' 5')-2'-dsoxy-(R )- P-thioadnylyl-(3' 5')-( R )-P -thiothymidylyl(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl-(3' 5')-2'-dsoxy-( R )- P-thiocytidylyl(3' 5')-2'-dsoxy-(R )- P-thioguanylyl-(3' 5')-( R )-P -thiothymidylyl(3' 5')-2'-dsoxy-( R )-P -thiocytidylyl-(3' 5')-2'-dsoxyadnosine nonadcasodique 2'-desoxi-(R )- P-tioguanilil-(3' 5')-2'-desoxi-(R )- P-tiocitidilil(3' 5')-2'-desoxi-(R )-P-tiocitidilil-(3'5')-2'-desoxi-(R )-P-tiocitidilil(3'5')-2'-desoxi-( R)- P-tioadenilil-(3'5')-2'-desoxi-(R )-P -tioadenilil(3'5')-2'-desoxi-( R)- P-tioguanilil-(3'5')-2'-desoxi-( R)- P-tiocitidilil(3' 5')-(R)- P-tiotimidilil-(3' 5')-2'-desoxi-(R)-P-tioguanilil-(3' 5')-2'-desoxi( R)- P-tioguanilil-(3'5')-2'-desoxi-(R )- P-tiocitidilil-(3' 5')-2'-desoxi(R )-P-tioadenilil-(3'5')-(R )-P-tiotimidilil-(3'5')-2'-desoxi-(R)-P-tiocitidilil(3'5')-2'-desoxi-( R)- P-tiocitidilil-(3' 5')-2'-desoxi-(R )- P-tioguanilil(3'5')-(R)-P-tiotimidilil-(3'5')-2'-desoxi-(R)-P-tiocitidilil(3'5')-2'-desoxiadenosina nonadecasdica C192H225N75Na19O98P19S19

alicaforsen

alicaforseno

alilusemum alilusem alilusem alilusem

7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1H )-one ( E)- O-sulfooxime (E)-O-sulfooxime de 7-chloro-1-(2-mthylbenzoyl)-2,3-dihydroquinolin4(1 H )-one (E)-O-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1H)-ona C17H15ClN2O5S
O N N CH3 O Cl SO3H

84

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

ambrisentanum ambrisentan ambrisentan ambrisentn

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid (+)-acide (2S)-2-[(4,6-dimthylpyrimidin-2-yl)oxy]-3-mthoxy3,3-diphnylpropanoque (+)-cido (2S)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico C22H22N2O4

CO2H H H3CO O N N

CH 3

CH 3

amdoxovirum amdoxovir amdoxovir amdoxovir

[(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol [(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]mthanol [(2R,4R)-4-(2,6-diamino-9H-purin-9-il)-1,3-dioxolan-2-il]metanol C9H12N6O3


NH2 N H2N N HO O O H N N H

amelubantum amelubant amlubant amelubant

ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]= oxy]phenyl](imino)methyl]carbamate [[4-[[3-[[4-[1-(4-hydroxyphnyl)-1-mthylthyl]phnoxy]mthyl]benzyl]oxy]= phnyl](imino)mthyl]carbamate dthyle [[4-[[3-[[4-[1-(4-hidroxifenil)-1-metiletil]fenoxi]metil]bencil]oxi]fenil](imino)metil]= carbamato de etilo

85

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C33H34N2O5
O H 3C O N H O O OH NH

H3C

CH3

amotosalenum amotosalen amotosalne amotosaleno

3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g][1]benzopyran-7-one 3-[(2-aminothoxy)mthyl]-2,5,9-trimthyl-7H-furo[3,2-g][1]benzopyran-7-one 3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7H-furo[3,2-g][1]benzopiran-7-ona C17H19NO4


O H 2N H3C O CH3 O O CH3

bimatoprostum bimatoprost bimatoprost bimatoprost

( Z)-7-[(1 R,2 R ,3R ,5 S)-3,5-dihydroxy-2-[(1 E,3S)-3-hydroxy-5-phenyl1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide ( Z)-7-[(1R ,2R ,3R ,5S )-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phnylpent1-nyl]cyclopentyl]-N-thylhept-5-namide (Z)-7-[(1 R,2R,3R ,5S)-3,5-dihidroxi-2-[(1 E,3 S)-3-hidroxi-5-fenilpent1-enil]ciclopentil]-N-etilhept-5-enamida C25H37NO4
OH

H O

H N

CH3

HO

H OH

86

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

caldaretum caldaret caldaret caldaret

5-methyl-2-(piperazin-1-yl)benzenesulfonic acid acide 5-mthyl-2-(piprazin-1-yl)benznesulfonique cido 5-metil-2-(piperazin-1-il)bencenosulfnico C11H16N2O3S


H3C SO3H N NH

cipralisantum cipralisant cipralisant cipralisant

4-[(1R,2R )-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H -imidazole 4-[(1R,2R )-2-(5,5-dimthylhex-1-ynyl)cyclopropyl]-1H -imidazole 4-[(1R,2R)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1H-imidazol C14H20N2


H N CH 3 HN H 3C CH3 H

darbepoetinum alfa darbepoetin alfa darbpotine alfa darbepoetina alfa

[30-L-asparagine,32-L-thronine,87- L-valine,88-L-asparagine, 90-L-threonine]erythropoietin (human) [30-L-asparagine,32-L-thronine,87-L-valine,88-L-asparagine, 90-L-thronine]rythropoitine humaine [30-L-asparagina,32-L-treonina,87- L-valina,88-L-asparagina, 90-L-treonina]eritropoietina humana C800H1300N228O243S5

APPRLICDSR VPDTKVNFYA LVNSSQVNET PPDAASAAPL CRTGD

VLERYLLEAK WKRMEVGQQA LQLHVDKAVS RTITADTFRK

EAENITTGCN VEVWQGLALL GLRSLTTLLR LFRVYSNFLR

ETCSLNENIT SEAVLRGQAL ALGAQKEAIS GKLKLYTGEA

87

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

drotrecoginum alfa (activatum) drotrecogin alfa (activated) drotrcogine alfa (activ) drotrecogina alfa (activada)

blood coagulation factor XIV (human) facteur XIV humain de coagulation sanguine factor XIV de coagulacin sangunea (humano) C2071H3165N581O640S31

ANSFLJJLRH WSKHVDGDQC RSGWEGRFCQ APGYKLGDDL

SSLJRJCIJJ LVLPLEHPCA
* REVSFLNCSL

ICDFJJAKJI SLCCGHGTCI DNGGCTHYCL CGRPWKRMEK

FQNVDDTLAF BGIGSFSCDC EEVGWRRCSC KRSHL DTE

LQCHPAVKFP

DQEDQVDPRL IHPSWVLTAA KEVFVHPNYS SGLAERELNQ


* IKIPVVPHNE *

IDGKMTRRGD HCMDESKKLL KSTTDNDIAL AGQETLVTGW CSEVMSNMVS TWFLVGLVSW EAPQKSWAP


HO B=

SPWQVVLLDS VRLGEYDLRR LHLAQPATLS GYHSSREKEA ENMLCAGILG GEGCGLLHNY


CO2H H N H J= O

KKKLACGAVL WEKWELDLDI QTIVPICLPD


* KRNRTFVLNF

DRQDACEGDS GVYTKVSRYL
HO2C CO2H H N H

GGPMVASFHG DWIHGHIRDK

* glycosylation sites * sites de glycosylation * posiciones de glicosilacin

ecalcidenum ecalcidene calcidne ecalcideno

1-[(5Z,7E,20S)-1,3-dihydroxy-9,10-secochola-5,7,10(19)-trien24-oyl]piperidine 1-[(5Z,7E,20S)-1,3-dihydroxy-9,10-scochola-5,7,10(19)-trin24-oyl]pipridine 1-[(5Z,7 E,20S)-1,3-dihidroxi-9,10-secocola-5,7,10(19)-trien24-oil]piperidina

88

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C29H45NO3
H3C H CH3 H N O

H CH2 HO H H OH

efalizumabum efalizumab

immunoglobulinG1, anti-(human antigen CD11a) (human-mouse monoclonal hu1124 1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer immunoglobulineG1, anti-(antigne CD11a humain) (chane1 de lanticorps monoclonal de souris humanis hu1124),dimre du disulfure avec la chane lgre de lanticorps monoclonal de souris humanis hu1124 inmunoglobulinaG1, anti-(antgeno CD11a humano) (cadena1 del anticuerpo monoclonal humanizado de ratn hu1124), dmero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratn hu1124

falizumab

efalizumab

enfuvirtidum enfuvirtide

L-leucyl-L-isoleucyl-L--glutamyl-L--glutamyl-L-seryl-L-glutaminyl-

acetyl-L-tyrosyl- L-threonyl-L-seryl- L-leucyl-L-isoleucyl- L-histidyl-L-seryl-

L-asparaginyl-L-glutaminyl-L-glutaminyl-L--glutamyl-L-lysyl-L-asparaginylL--aspartyl- L-lysyl-L-tryptophyl-L-alanyl- L-seryl-L -leucyl-L-tryptophylL-asparaginyl-L-tryptophyl-L-phenylalaninamide

L--glutamyl-L-glutaminyl-L--glutamyl-L-leucyl-L-leucyl-L--glutamyl-L-leucyl-

enfuvirtide

L-leucyl-L-isoleucyl-L--glutamyl-L--glutamyl-L-sryl-L-glutaminyl-

actyl-L-tyrosyl- L-thronyl-L-sryl- L-leucyl-L-isoleucyl- L-histidyl-L-sryl-

L-asparaginyl-L-glutaminyl-L-glutaminyl-L--glutamyl-L-lysyl-L-asparaginylL--aspartyl- L-lysyl-L-tryptophyl-L-alanyl- L-sryl-L -leucyl-L-tryptophylL-asparaginyl-L-tryptophyl-L-phnylalaninamide

L--glutamyl-L-glutaminyl-L--glutamyl-L-leucyl-L-leucyl-L--glutamyl-L-leucyl-

enfuvirtida

acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucilL-isoleucil-L--glutamil-L--glutamil-L-seril-L-glutaminil-L-asparaginil-L-glutaminilL-glutaminil-L--glutamil-L-lisil-L-asparaginil-L--glutamil-L-glutaminil-L--glutamilL-leucil-L-leucil-L--glutamil-L-leucil-L--aspartil-L-lisil-L-triptofil-L-alanil-L-serilL-leucil-L-triptofil-L-asparaginil-L-triptofil-L-fenilalaninamida

89

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C204H301N51O64

H3C

Tyr

Thr Gln Lys

Ser Gln Trp

Leu Glu Ala


30

Ile His Asn Leu

Ser Glu
20

Leu Gln Asn

Ile Glu Trp

Glu
10

Glu Leu

Ser Glu

O Gln Asn Leu Asp

Lys Ser

Leu

Trp

Phe NH2

epafipasum epafipase pafipase epafipasa

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine deacetylase-(6-400)-peptide (human) dsactylase-(6-400)-peptide (humaine) de la 2-actyl-1-alkyl-sn-glycro3-phosphocholine 1-O-alquil-2-acetil-sn-glicero-3-fosfocolina 6-400-desacetilasa (humana) C2016H3107N545O586S14

AAASFGQTKI SQDNDRLDTL SMTTPANWNS LASHGFIVAA RTLKQEEETH NALDLKFDME QRFRCGIALD NIIKMKKCYS HMLKLKGDID CLIEGDDENL

PRGNGPYSVG WIPNKEYFWG PLRPGEKYPL VEHRDRSASA IRNEQVRQRA QLKDSIDREK AWMFPLGDEV PDKERKMITI SNVAIDLSNK IPGTNINTTN

CTDLMFDHTN LSKFLGTHWL VVFSHGLGAF TYYFKDQSAA KECSQALSLI IAVIGHSFGG YSRIPQPLFF RGSVHQNFAD ASLAFLQKHL QHIMLQNSSG

KGTFLRLYYP MGNILRLLFG RTLYSAIGID EIGDKSWLYL LDIDHGKPVK ATVIQTLSED INSEYFQYPA FTFATGKIIG GLHKDFDQWD IEKYN

epoetinum delta epoetin delta potine delta epoetina delta

1-165-erythropoietin (human HMR4396), glycoform 1-165-rythropoitine (humaine HMR4396), glycoforme 1-165-eritropoietina (humana HMR4396), glicoforma

90

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C809H1301N229O240S5
* EAENITTGCA * EHCSLNENIT

APPRLICDSR VPDTKVNFYA LVNSSQPWEP


* PPDAASAAPL *

VLERYLLEAK WKRMEVGQQA LQLHVDKAVS RTITADTFRK

VEVWQGLALL GLRSLTTLLR LFRVYSNFLR

SEAVLRGQAL ALGAQKEAIS GKLKLYTGEA

CRTGD
* : glycosylation sites / sites de glycosylation / posiciones de glicosilacin

erlotinibum erlotinib erlotinib erlotinib

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine N-(3-thynylphnyl)-6,7-bis(2-mthoxythoxy)quinazolin-4-amine N-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina C22H23N3O4


H3 C H3 C O O HN N N CH

O O

febuxostatum febuxostat fbuxostat febuxostat

2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid acide 2-[3-cyano-4-(2-mthylpropoxy)phnyl]-4-mthylthiazole5-carboxylique cido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxlico C16H16N2O3S


CH3 N S H3C CH3 O CN CO2H

91

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

feloprentanum feloprentan floprentan feloprentn

(2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]3,3-diphenylpropanoic acid acide (2S)-3-[2-(3,4-dimthoxyphnyl)thoxy]-2-[(4,6-dimthylpyrimidin2-yl)oxy]-3,3-diphnylpropanoque cido (2S)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]3,3-difenilpropanoico C31H32N2O6


CO2H H N O H3CO H3CO O N CH3 CH3

finafloxacinum finafloxacin finafloxacine

(-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4a S,7a S)-hexahydropyrrolo[3,4- b ]1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7a S)hexahydropyrrolo[3,4- b]-1,4-oxazin-6(2 H)-yl)-4-oxo-1,4-dihydroquinoline3-carboxylique (-)-cido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-hexahidropirrolo[3,4-b]1,4-oxazin-6(2H)-il)-4-oxo-1,4-dihidroquinolina-3-carboxlico C20H19FN4O4
NH H CN O H N N

finafloxacino

F O

CO2H

gadomelitolum gadomelitol

hydrogen [2,2',2',2'-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tetrakis= [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2 S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl2,4,6-tribromo]carbamoyl]phenyl]amino]-2-oxoethyl]carbamoyl]phenyl]= carbamoyl]phenyl]amino]-2-oxoethyl]amino]-5-oxopentanoato](4-)]= gadolinate(1-) hydrogno-[2,2',2',2'-[1,4,7,10-ttraazacyclododcane-1,4,7,10-triyl]ttrakis [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2 S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl2,4,6-tribromo]carbamoyl]phnyl]amino]-2-oxothyl]carbamoyl]phnyl]= carbamoyl]phnyl]amino]-2-oxothyl]amino]-5-oxopentanoato](4-)]= gadolinate(1-)

gadomlitol

92

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

gadomelitol

hidrgeno-[2,2',2',2'-[1,4,7,10-tetraazaciclododecano-1,4,7,10-triil]tetrakis= [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3 R,4R,5R)-2,3,4,5,6-pentahidroxihexil2,4,6-tribromo]carbamoil]fenil]amino]-2-oxoetil]carbamoil]fenil]carbamoil]fenil]= amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]gadolinato(1-) C228H313Br12GdN32O116


R O2C N N R R N Gd 3+ HO2C N R OH OH CO2O HN CO2 H N O H2C NH Br N Br O HO OH OH OH OH OH OH OH OH OH H N

NH O

O Br

R- =

HO OH OH OH HO OH OH N

O OH

garnocestimum garnocestim garnocestim garnocestim

5-73-macrophage inflammatory protein2 (human gene gro2) CXCchimiokineGRO-(5-73)-peptide (GRO: protine inflammatoire humaine scrte par les macrophages) CXCquimiokinaGRO-(5-73)-pptido (GRO: protena inflamatoria humana secretada por los macrfagos) C325H557N97O95S6

TELRCQ IATLKNGQKA

CLQTLQGIHL CLNPASPMVK

KNIQSVKVKS KIIEKMLKNG

PGPHCAQTEV KSN

gefitinibum gefitinib gfitinib gefitinib

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin4-yl)propoxy]quinazolin-4-amine N-(3-chloro-4-fluorophnyl)-7-mthoxy-6-[3-(morpholin4-yl)propoxy]quinazolin-4-amine N-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin4-amina

93

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C22H24ClFN4O3
H 3CO N O O HN N N Cl

ingliforibum ingliforib ingliforib ingliforib

5-chloro- N-[(1 S,2R )-1-benzyl-3-( cis-3,4-dihydroxypyrrolidin-1-yl)2-hydroxy-3-oxopropyl]-1 H -indole-2-carboxamide 5-chloro- N-[(1 S,2R )-1-benzyl-3-( cis-3,4-dihydroxypyrrolidin-1-yl)2-hydroxy-3-oxopropyl]-1 H -indole-2-carboxamide 5-cloro-N -[(1S,2R)-1-bencil-3-(cis-3,4-dihidroxipirrolidin-1-il)-2-hidroxi3-oxopropil]-1H-indol-2-carboxamida C23H24ClN3O5

H N

O N H

O N OH H H OH

H OH

Cl

ipravacainum ipravacaine ipravacane ipravacana

(2RS)-1-(cyclopropylmethyl)-2',6'-dimethyl-2-piperidinecarboxanilide (2RS)-1-(cyclopropylmthyl)-N -(2,6-dimthylphnyl)pipridine-2-carboxamide (2RS)-1-(ciclopropilmetil)-N -(2,6-dimetilfenil)piperidina-2-carboxamida C18H26N2O

CH3

H H N O CH3

and enantiomer et nantiomre y enantimero

94

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

isegananum iseganan

L-arginylglycylglycyl-L-leucyl- L-cysteinyl-L -tyrosyl-L-cysteinyl-L -arginylglycylL-arginyl-L-phenylalanyl-L-cysteinyl-L-valyl- L-cysteinyl-L-valylglycylL-argininamide

cyclic (514),(712)-bis(disulfide)

isganan

(514),(712)-bis(disulfure cyclique) de L-arginyl-glycyl-glycyl-L-leucylL-cystinyl-L-tyrosyl- L-cystinyl-L-arginyl-glycyl- L-arginyl- L-phnylalanylL-cystinyl-L-valyl-L-cystinyl-L-valyl-glycyl-L-argininamide (514),(712)-bis(disulfuro cclico) de L-arginil-glicil-glicil-L-leucil-L-cisteinilL-tirosil-L-cisteinil-L-arginil-glicil-L-arginil-L-fenilalanil-L-cisteinil-L-valil-L-cisteinilL-valil-glicil-L-argininamida C78H126N30O18S4

isegann

H Arg Val

Gly Cys

Gly Val

Leu Gly

Cys

Tyr

Cys

Arg

Gly

Arg

Phe

Cys

Arg NH2

labetuzumabum labetuzumab

immunoglobulinG, anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 -chain), disulfide with human-mouse monoclonal hMN-14 -chain, dimer immunoglobulineG, anti-(antigne carcinoembryonnaire humain) (chane- de lanticorps monoclonal de souris humanis hMN-14), dimre du disulfure avec la chane- de lanticorps monoclonal de souris humanis hMN-14 inmunoglobulinaG, anti-(antgeno carcinoembrionario humano) (cadena- del anticuerpo monoclonal humanizado de ratn hMN-14), dmero del disulfuro con la cadena- del anticuerpo monoclonal humanizado de ratn hMN-14

labtuzumab

labetuzumab

laniquidarum laniquidar laniquidar laniquidar

methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate 11-[1-[2-[4-(quinolin-2-ylmthoxy)phnyl]thyl]pipridin-4-ylidne]6,11-dihydro-5H-imidazo[2,1-b][3]benzazpine-3-carboxylate de mthyle 11-[1-[2-[4-(quinolin-2-ilmetoxi)fenil]etil]piperidin-4-ilideno]-6,11-dihidro5H-imidazo[2,1-b][3]benzazepina-3-carboxilato de metilo

95

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C37H36N4O3

O H3 C O

N N N

O N

lapisteridum lapisteride lapistride lapisterida

N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5 -androst-1-ene17-carboxamide N-[1-(4-mthoxyphnyl)-1-mthylthyl]-3-oxo-4-aza-5-androst-1-ne17-carboxamide N- [1-(4-metoxifenil)-1-metiletil]-3-oxo-4-aza-5-androst-1-eno17-carboxamida C29H40N2O3


O CH3 CH3 H O N H H H H OCH3 H N H

CH3 CH3

laquinimodum laquinimod laquinimod laquinimod

5-chloro-N -ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline3-carboxamide 5-chloro-N-thyl-4-hydroxy-1-mthyl-2-oxo- N-phnyl-1,2-dihydroquinoline3-carboxamide 5-cloro-N-etil-4-hidroxi-1-metil-2-oxo-N-fenil-1,2-dihidroquinolina3-carboxamida

96

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C19H17ClN2O3
CH3 N O N Cl OH O CH3

laronidasum laronidase laronidase laronidasa

8-L-histidine--L-iduronidase (human) [8-L-histidine]--L-iduronidase humaine 8-L-histidina--L-iduronidasa (humana) C3169H4854N901O884S12

AEAPHLVHVD LSWDQQLNLA GLSYNFTHLD KQQVFEWKDL HDFDNVSMTM HTPPRSPLSW ARSSISILEQ WSLPQPWRAD LSNDNAFLSY VLTAMGLLAL RPQGPADAWR GPGLVYVTRY AAEDPVAAAP KPPGQVTRLR SQDGKAYTPV WARPGPFSDP
* *

AARALWPLRR YVGAVPHRGI GYLDLLRENQ VSSLARRYIG QGFLNYYDAC GLLRHCHDGT EKVVAQQIRQ VTYAAMVVKV HPHPFAQRTL LDEEQLWAEV AAVLIYASDD LDNGLCSPDG RPLPAGGRLT ALPLTQGQLV SRKPSTFNLF VPYLEVPVPR

FWRSTGFCPP KQVRTHWLLE LLPGFELMGS RYGLAHVSKW SEGLRAASPA NFFTGEAGVR LFPKFADTPI IAQHQNLLLA


* TARFQVNNTR *

LPHSQADQYV LVTTRGSTGR ASGHFTDFED NFETWNEPDH LRLGGPGDSF LDYISLHRKG YNDEADPLVG


* NTTSAFPYAL

PPHVQLLRKP HTVGVLASAH VTLRLRGVPP PTAEQFRRMR LLVHVCARPE KCLWTYEIQF GSYRVRALDY

SQAGTVLDSN TRAHPNRSVA EWRRLGRPVF LRPALRLPSL LVWSDEHVGS VFSPDTGAVS GPPSPGNP


*

* : glycosylation sites / sites de glycosylation / posiciones de glicosilacin : disulfide / disulfure / disulfuro

97

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

lirimilastum lirimilast lirimilast lirimilast

2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate mthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uridobenzofuran-6-yle metanosulfonato de 2-(2,4-diclorobenzoil)-3-ureidobenzofuran-6-ilo C17H12Cl2N2O6S


O O H3C S O O O O NH NH2 Cl Cl

livaraparinum calcium livaraparin calcium

calcium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-O-sulfo--L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-structure at the reducing end of their chain; the mass-average molecular mass ranges between 3000 and 5000 with 75% is less than 8000; the degree of sulfatation is approximately 2 per disaccharidic unit sel calcique dune hparine de basse masse molculaire obtenue par dpolymrisation, au moyen dacide nitreux, dhparine de muqueuse intestinale de porc; la majorit des composants de la livaraparine calcique possdent une structure acide 2-O-sulfo--L-idopyranosuronique lextrmit non rductrice de leur chane et une structure 6-O-sulfate lextrmit rductrice de leur chane; la masse molculaire relative moyenne est de 3000 5000, 75% tant infrieur 8000; le degr de sulfatation par unit disaccharide est voisin de 2 sal clcica de una heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerizacin con cido nitroso; la mayora de los componentes de la livaraparina clcica tienen cido 2-O-sulfo-L-idopiranosurnico en el extremo no reductor de la cadena y una estructura 6-O-sulfatada en el extremo reductor de la cadena; la masa molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el grado de sulfatacin por unidad de disacrido es aproximadamente 2

livaraparine calcique

livaraparina clcica

manifaxinum manifaxine manifaxine manifaxina

(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol (2S,3S,5R)-2-(3,5-difluorophnyl)-3,5-dimthylmorpholin-2-ol (2S,3S,5R)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol

98

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C12H15F2NO2
CH3 H NH H CH3 F

HO

miglustatum miglustat miglustat miglustat

(2R,3R,4 R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (2R,3R,4 R,5S)-1-butyl-2-(hydroxymthyl)pipridine-3,4,5-triol (2R,3R,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol C10H21NO4


OH

HO H HO

N H OH

CH3

miriplatinum miriplatin miriplatine miriplatino

(SP -4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N ,N ]= bis(tetradecanoato-O)platinum (SP -4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N ,N ]= bis(ttradcanoato-O)platine (SP-4-2)-[(1R ,2R)-ciclohexano-1,2-diamina-N,N]= bis(tetradecanoato-O)platino C34H68N2O4Pt
H3C O Pt O H3 C O N H2 H O H2 H N

99

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

mirostipenum mirostipen mirostipen mirostipeno

[23-methionine]human myeloid progenitor inhibitory factor1-(23-99)-peptide [23-mthionine]facteur1 dinhibition du prcurseur mylode humain(23-99)-peptide [23-metionina]-(23-99)-pptido del factor1 de inhibicin del progenitor mieloide humano C380H614N112O113S9

MDRFHATS SIPCSLLESY VQVCMRMLKL FETNSECSKP DTRIKTRKN GVIFLTKKGR

ADCCISYTPR RFCANPSDKQ

mureletecanum mureletecan

poly[[N-(2-hydroxypropyl)methacrylamide]-co-[camptothecin ester with N-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-co-[N-[[(2hydroxypropyl)carbamoyl]methyl]methacrylamide]] copolymre de N-[(2RS)-2-hydroxypropyl]-2-mthylpropnamide, de N-[2-[[6-[[2-[[(4S)-4-thyl-3,14-dioxo-3,4,12,14-ttrahydro1H-pyrano[3,4:6,7]indolizino[1,2-b]quinolin-4-yl]oxy]-2-oxothyl]amino]6-oxohexyl]amino]-2-oxothyl]-2-mthylpropnamide et de N-[2-[[(2RS)-2-hydroxypropyl]amino]-2-oxothyl]-2-mthylpropnamide poli[[N-(2-hidroxipropil)metacrilamida]-co-[ ster de camptotecina con N-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-co-[N-[[(2hidroxipropil)carbamoil]metil]metacrilamida]]

murltcan

mureletecn

O N O O CH3 O O HN CH3 H3C OH NH CH3 O


x y z

HO NH O HN O NH CH3 O NH CH3

100

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

nasaruplasum beta nasaruplase beta nasaruplase bta

prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety), glycosylated (murine cell line SP2/0) prourokinase (activateur denzyme) humaine glycosyle dont le gne est clon dans le vecteur pUK4/pUK18 et exprime dans la ligne cellulaire murine SP2/0 prourokinasa (activador de enzima) humana glicosilada cuyo gen se clona en el vector pUK4/pUK18 y se expresa en la lnea celular murina SP2/0 C2031H3121N585O601S31

nasaruplasa beta

SNELHQVPSN HCEIDKSKTC QQTYHAHRSD PLVQECMVHD GGEFTTIENQ SATHCFIDYP LHKDYSADTL PSMYNDPQFG SHRECQQPHY VCSLQGRMTL SHTKEENGLA

* CDCLNGGTCV

SNKYFSNIHW KASTDTMGRP YCRNPDNRRR PEELKFQCGQ RGGSVTYVCG RSRLNSNTQG IRSKEGRCAQ ENSTDYLYPE CAADPQWKTD ALKDKPGVYT
*

CNCPKKFGGQ CLPWNSATVL PWCYVQVGLK KTLRPRFKII GSLISPCWVI EMKFEVENLI PSRTIQTICL QLKMTVVKLI SCQGDSGGPL RVSHFLPWIR

YEGNGHFYRG ALQLGLGKHN CADGKKPSSP PWFAAIYRRH KKEDYIVYLG AHHNDIALLK TSCEITGFGK YGSEVTTKML TGIVSWGRGC L

* : glycosylation sites / sites de glycosylation / posiciones de glicosilacin

netoglitazonum netoglitazone ntoglitazone netoglitazona

(5RS)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine2,4-dione (5RS)-5-[[6-[(2-fluorophnyl)mthoxy]naphtaln-2-yl]mthyl]thiazolidine2,4-dione (5RS)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiazolidina-2,4-diona C21H16FNO3S

O O F S H NH O and enantiomer et nantiomre y enantimero

101

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

ospemifenum ospemifene ospmifne ospemifeno

2-[p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol (Z)-2-[4-(4-chloro-1,2-diphnylbut-1-nyl)phnoxy]thanol 2-[p-[(Z)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol C24H23ClO2

O Cl

OH

pegfilgrastimum pegfilgrastim pegfilgrastim pegfilgrastim

N-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with -methyl- -hydroxypoly(oxyethylene) N-(3-hydroxypropyl)mthionylfacteur de stimulation de colonie humain, 1-ther avec le -mthyl--hydroxypoly(oxythylne) N-(3-hidroxipropil)metionilfactor de estimulacin de colonias humano, 1-ter con el -metil--hidroxipoli(oxietileno) C849H1347N223O244S9,(C2H4O)n
H3 C O
n

TPLGPASSLP LCHPEELVLL GLFLYQGLLQ MEELGMAPAL LEVSYRVLRH

QSFLLKCLEQ GHSLGIPWAP ALEGISPELG QPTQGAMPAF LAQP

VRKIQGDGAA LSSCPSQALQ PTLDTLQLDV ASAFQRRAGG

LQEKLCATYK LAGCLSQLHS ADFATTIWQQ VLVASHLQSF

pexelizumabum pexelizumab pexlizumab pexelizumab

immunoglobulin, anti-(human complement C5 -chain) (human-mouse monoclonal 5G1.1-SC single chain) immunoglobuline, anti-(chane- du complment C5 humain) (mono chane de lanticorps monoclonal de souris humanis 5G1.1-SC) inmunoglobulina, anti-(cadena- del complemento C5 humano) (mono cadena del anticuerpo monoclonal humanizado de ratn 5G1.1-SC)

102

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

pralnacasanum pralnacasan

(1 S,9S)- N -[(2 R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a][1,2]= diazepine-1-carboxamide (1 S,9S)- N -[(2R,3S)-2-thoxy-5-oxottrahydrofuran-3-yl]-9-[(isoquinolin1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a]= [1,2]diazpine-1-carboxamide (1S,9S)-N -[(2R,3 S)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin1-ilcarbonil)amino]-6,10-dioxooctahidro-6-H-piridazino[1,2-a][1,2]diazepina1-carboxamida C26H29N5O7

pralnacasan

pralnacasn

O N O H H N O H N N O

H N H H O O

CH3

pratosartanum pratosartan pratosartan pratosartn

2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]5,6,7,8-tetrahydrocycloheptaimidazol-4(3H)-one 2-propyl-3-[[2'-(1H-ttrazol-5-yl)biphnyl-4-yl]mthyl]5,6,7,8-ttrahydrocycloheptaimidazol-4(3H)-one 2-propil-3-[[2'-(1H-tetrazol-5-il)bifenil-4-il]metil]5,6,7,8-tetrahidrocicloheptaimidazol-4(3H)-ona C25H26N6O


O

N N HN N

N N CH3

ragaglitazarum ragaglitazar ragaglitazar ragaglitazar

(-)-(2S)-2-ethoxy-3-[4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl]propanoic acid (-)-acide (2S)-2-thoxy-3-[4-[2-(10H -phnoxazin-10-yl)thoxy]phnyl]= propanoque (-)-cido (2S)-2-etoxi-3-[4-[2-(10H-fenoxazin-10-il)etoxi]fenil]propanoico

103

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C25H25NO5

N O

O H O

CH3

CO2H

reslizumabum reslizumab

immunoglobulin G4, anti-(human interleukin5) (human-rat monoclonal SCH55700 4-chain), disulfide with human-rat monoclonal SCH55700 light chain, dimer immunoglobuline G4, anti-(interleukine5 humaine ), (chane4 de lanticorps monoclonal de rat humanis SCH55700), dimre du disulfure avec la chane lgre de lanticorps monoclonal de rat humanis SCH55700 immunoglobulina G4, anti-(interleukina5 humana ), (cadena4 del anticuerpo monoclonal humanizado de rata SCH55700), dmero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de rata SCH55700

reslizumab

reslizumab

ruboxistaurinum ruboxistaurin

(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene18,20-dione (9S)-9-[(dimthylamino)mthyl]-6,7,10,11-ttrahydro-9H,19H-5,21:12,17dimthnodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadcne18,20-dione (9S)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9H,19H-5,21:12,17dimetenodibenzo[e,k]pirrolo[3,4-h][1,4,13]oxadiazaciclohexadeceno18,20-diona C28H28N4O3

ruboxistaurine

ruboxistaurina

H N

N CH3 H3C N H O

104

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

semaxanibum semaxanib smaxanib semaxanib

3-[(Z)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (Z)-3-[(3,5-dimthyl-1H-pyrrol-2-yl)mthylne]-1,3-dihydro-2 H-indol-2-one 3-[(Z)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona C15H14N2O


CH3 HN

HN

CH3

senazodanum senazodan snazodan senazodn

6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2H)-one 6-[4-(pyridin-4-ylamino)phnyl]-4,5-dihydropyridazin-3(2H)-one 6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2H)-ona C15H14N4O


H N

N N N H

silodosinum silodosin silodosine silodosina

(-)-1-(3-hydroxypropyl)-5-[(2 R )-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]= ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide (-)-1-(3-hydroxypropyl)-5-[(2 R )-2-[[2-[2-(2,2,2-trifluorothoxy)phnoxy]= thyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide (-)-1-(3-hidroxipropil)-5-[(2 R)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]= amino]propil]-2,3-dihidro-1H-indol-7-carboxamida C25H32F3N3O4

O F3C O

H N H CH3

O NH2 N OH

105

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

solifenacinum solifenacin solifnacine solifenacina

(3R)-1-azabicyclo[2.2.2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline2(1H )-carboxylate (1S)-1-phnyl-3,4-dihydroisoquinoline-2(1H)-carboxylate de (3 R)-1-azabicyclo[2.2.2]oct-3-yle (1S)-1-fenil-3,4-dihidroisoquinolina-2(1H)-carboxilato de (3R)-1-azabiciclo[2.2.2]oct-3-ilo C23H26N2O2

H N

H O N

tadalafilum tadalafil tadalafil tadalafilo

(6R ,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione (6R ,12aR)-6-(1,3-benzodioxol-5-yl)-2-mthyl2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione (6R,12aR)-6-(1,3-benzodioxol-5-il)-2-metil2,3,6,7,12,12a-hexahidropirazino[1',2':1,6]pirido[3,4-b]indol-1,4-diona C22H19N3O4


H O N N H O O N H O CH 3

tafluposidum tafluposide

4-[(5R ,5aR,8aR ,9S)-9-[[4,6-O-[(1R )-ethylidene]2,3-bisO-[(pentafluorophenoxy)acetyl]-- D-glucopyranosyl]oxy]-6-oxo5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]2,6-dimethoxyphenyle dihydrogen phosphate dihydrognophosphate de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-thylidne]2,3-bisO -[(pentafluorophnoxy)actyl]--D-glucopyranosyl]oxy]-6-oxo5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphto[2,3- d]-1,3-dioxol-5-yl]2,6-dimthoxyphnyle dihidrgenofosfato de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-etilideno]2,3-bisO-[(pentafluorofenoxi)acetil]- -D-glucopiranosil]oxi]-6-oxo5,5a,6,8,8a,9-hexahidrofuro[3',4':6,7]nafto[2,3-d]-1,3-dioxol-5-il]2,6-dimetoxifenilo

tafluposide

taflupsido

106

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

C45H35F10O20P
F F F O F O H H3C O O O F F O O O OCH 3 O O O O O F H H H O H OCH3 O P OH OH O

F F

telberminum telbermin telbermine telbermina

vascular endothelial growth factor (human), dimer facteur de croissance de lendothlium vasculaire humain (dimre) factor de crecimiento del endotelio vascular (humano), dmero C1612H2536N500O498S44

APMAEGGGQN DEIEYIFKPS MRIKPHQGQH SERRKHLFVQ DKPRR

HHEVVKFMDV CVPLMRCGGC IGEMSFLQHN

YQRSYCHPIE CNDEGLECVP

TLVDIFQEYP TEESNITMQI

KCECRPKKDR ARQENPCGPC LELNERTCRC


2

DPQTCKCSCK NTDSRCKARQ

: disulfide / disulfure / disulfuro

tenivastatinum tenivastatin tnivastatine

(3R,5R)-7-[(1S,2 S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl1,2,6,7,8,8a-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid acide (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimthylbutanoyl)oxy]2,6-dimthyl-1,2,6,7,8,8a-hexahydronaphtaln-1-yl]3,5-dihydroxyheptanoque cido (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil1,2,6,7,8,8a-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico

tenivastatina

107

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

C25H40O6
CO2H OH H H O H H 3C H CH3 CH3 O CH3

CH3 H

H OH

tesaglitazarum tesaglitazar tsaglitazar tesaglitazar

(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]= propanoic acid acide (2S)-2-thoxy-3-[4-[2-[4-[(mthylsulfonyl)oxy]phnyl]thoxy]phnyl]= propanoque cido (2S)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico C20H24O7S


O O O S H3C O H O CO2H CH3

tofimilastum tofimilast tofimilast tofimilast

9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H -pyrazolo[3,4-c]1,2,4-triazolo[4,3-a]pyridine 9-cyclopentyl-7-thyl-3-(thiophn-2-yl)-6,9-dihydro-5H -pyrazolo[3,4-c]1,2,4-triazolo[4,3-a]pyridine 9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5 H-pirazolo[3,4-c]1,2,4-triazolo[4,3-a]piridina C18H21N5S

N N N N H3C N S

108

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

xidecaflurum xidecaflur xidcaflur xidecaflur

2,2-[(9Z)-9-octadecenylimino]diethanol hydrofluoride fluorhydrate de 2,2-[(9Z)-octadec-9-nylimino]dithanol hidrofluoruro de 2,2 -[(9Z)-9-octadecenilimino]dietanol C22H46FNO2


H3C N OH , HF OH

zanapezilum zanapezil zanapzil zanapezilo

3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H -1-benzazepin8-yl)propan-1-one 3-(1-benzylpipridin-4-yl)-1-(2,3,4,5-ttrahydro-1H -1-benzazpin8-yl)propan-1-one 3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1H-1-benzazepin-8-il)propan1-ona C25H32N2O


O

N NH

zonampanelum zonampanel zonampanel zonampanel

[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin1(2H)-yl]acetic acid acide [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin1(2H )-yl]actique cido [7-(1H-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihidroquinoxalin1(2H)-il]actico C13H9N5O6


CO2H N N O2N N N H O O

109

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

zoniporidum zoniporide zoniporide zoniporida

N-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxamide N-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1 H-pyrazole4-carboxamide N-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1H -pyrazol-4-carboxamida C17H16N6O


O N N N H NH NH2

zoticasonum zoticasone zoticasone zoticasona

S-[(3R )-2-oxotetrahydrofuran-3-yl] 6,9-difluoro-12,17-dihydroxy16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate 6,9-difluoro-12,17-dihydroxy-16-mthyl-3-oxoandrosta-1,4-dine17-carbothioate de S-[(3R)-2-oxottrahydrofuran-3-yle] 6,9-difluoro-12,17-dihidroxi-16-metil-3-oxoandrosta-1,4-dieno17-carbotioato de S-[(3R)-2-oxotetrahidrofuran-3-ilo] C25H30F2O6S

O O HO H H H F CH3 H S OH CH3 H O

CH3 F O H

110

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended INN: List 47

AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTES AUX LISTES ANTRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Nonproprietary Names (Prop. INN): List 59 Dnominations communes internationales proposes (DCI Prop.): Liste 59 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59 (WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmaceuticas de la OMS, Vol. 2, No. 2, 1988) p. 16 delete/supprimer/suprimase levoglutamidum levoglutamide lvoglutamide levoglutamida insert/insrer/insrtese glutaminum glutamine glutamine glutamina

Recommended International Nonproprietary Names (Rec. INN): List 42 Dnominations communes internationales recommendes (DCI Rec.): Liste 42 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42 (WHO Drug Information, Vol. 13, No. 3, 1999) suprimase p. 184 carabersato p. 207 tonabersato insrtese carabersat tonabersat

Recommended International Nonproprietary Names (Rec. INN): List 44 Dnominations communes internationales recommendes (DCI Rec.): Liste 44 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44 (WHO Drug Information, Vol. 14, No. 3, 2000) p. 199 delete/supprimer/suprimase nebostinelum nebostinel nbostinel nebostinel p. 199 onerceptum onercept insert/insrer/insrtese neboglaminum neboglamine nboglamine neboglamina

replace the description by the following: TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated human Tumor Necrosis Factor Receptor1) sustityase la descripcin por la siguiente: pptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1 humano del factor de necrosis tumoral glicosilado)

onercept

111

Recommended INN: List 47

WHO Drug Information, Vol. 16, No. 1, 2002

Recommended International Nonproprietary Names (Rec. INN): List 45 Dnominations communes internationales recommendes (DCI Rec.): Liste 45 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45 (WHO Drug Information, Vol. 15, No. 1, 2001) p. 55 evernimicinum evernimicina sustityase la descripcin por la siguiente: O-3- C -metil-4-O-metil-3-nitro-2,3,6-tridesoxi--L - arabino-hexopiranosil(1 3)- O-4- O-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi-D- arabino -hexopiranosil-(1 4)- O-(1 R )-2,6-didesoxi- D- arabino hexopiranosilideno-(1 3-4)-O-3- C-metil-6-desoxi-- D-manopiranosil(13)- O-4-O-metil-6-desoxi- -D-galactopiranosil-(1 4)-2,6-di-O-metil-D-manopiranosido de O-(1R)-4-O-(2,4-dihidroxi-6-metilbenzoil)2,3-O-metileno-D-xilopiranosilideno-(1 3-4)--L-lixopiranosilo

Procedure and Guiding Principles / Procdure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in uneven numbers of proposed INN lists only. Les textes de la Procdure suivre en vue du choix de dnominations communes internationales recommandes pour les substances pharmaceutiques et des Directives gnrales pour la formation de dnominations communes internationales applicables aux substances pharmaceutiques seront publis seulement dans les numros impaires des listes des DCIs proposes. El texto de los Procedimientos de seleccin de denominaciones comunes internacionales recomendadas para las sustancias farmacuticas y de los Principios generales de orientacin para formar denominaciones comunes internacionales para sustancias farmacuticas aparece solamente en los nmeros impares de las listas de DCI propuestas.

112